Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New EU Approvals

Executive Summary

The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with two new products including Merck Sharp & Dohme's Ebola vaccine, Ervebo. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

You may also be interested in...



EU 2019 Approvals: Novel Therapies Make Strong Showing

Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019. 

Finance Watch: Forma Raises $100m In Quest To Become A Sickle Cell Leader

The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA. 

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141303

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel